Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | TEC | P42680 | 1/20 | 0.53 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18290007 | 1.00 | BTK (0.57) | BTKEGFRTECCD69 | |
| SCHEMBL23450721 | 1.00 | BTK (0.57) | BTKEGFRTECCD69 | |
| SCHEMBL18818235 | 0.92 | BTK (0.58) | BTKEGFRTECCD69 | |
| SCHEMBL18818236 | 0.92 | BTK (0.58) | BTKEGFRTECCD69 | |
| SCHEMBL31278860 | 0.89 | BTK (0.48) | BTKEGFRTECCD69 | |
| SCHEMBL32664572 | 0.89 | BTK (0.48) | BTKEGFRTECCD69 | |
| SCHEMBL31278388 | 0.89 | BTK (0.46) | BTKEGFRTECCD69 | |
| SCHEMBL32664420 | 0.89 | BTK (0.46) | BTKEGFRTECCD69 | |
| SCHEMBL31278495 | 0.88 | BTK (0.46) | BTKEGFRTECCD69 | |
| SCHEMBL32664459 | 0.88 | BTK (0.46) | BTKEGFRTECCD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250101021-A1 | METHODS OF MAKING TOLEBRUTINIB | PRINCIPIA BIOPHARMA INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4112618-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101021-A1 | METHODS OF MAKING TOLEBRUTINIB | ABL1, JAK2, JAK1 | BTK 37/4885EGFR 125/4885TEC 181/4885 |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | BTK 1/4885EGFR 237/4885TEC 12/4885 |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | BTK 1/4885EGFR 237/4885TEC 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.